<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870101</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00073558</org_study_id>
    <secondary_id>5UM1AI104681</secondary_id>
    <nct_id>NCT02870101</nct_id>
  </id_info>
  <brief_title>Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT</brief_title>
  <acronym>pNAAT</acronym>
  <official_title>Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis in Extragenital Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide data and analyses to support 510(k) applications to
      the FDA for multiple nucleic acid amplification tests (NAATs) diagnostic platforms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background &amp; Significance: Infections due to Neisseria gonorrhoeae (NG) and Chlamydia
      trachomatis (CT) are major threats to public health. In 2008, the World Health Organization
      (WHO) estimated more than 100 million new worldwide cases for each of NG and CT. In 2013,
      there were 333,000 NG and 1.4 million CT genitourinary infections in the US. Most CT and NG
      infections are asymptomatic, but infection can lead to serious sequelae, including
      infertility, chronic pelvic pain, adverse obstetrical outcomes, increased risk of acquiring
      the human immunodeficiency virus (HIV), and disseminated infection.

      There has also been growing concern over antibiotic resistance. In 2013, the US Centers for
      Disease Control and Prevention (CDC) classified drug-resistant NG as one of the three
      urgent-level resistant bacteria. Improved detection of extragenital NG is thought to be a
      crucial component of adequate treatment and for prevention of further resistance.

      Currently, the CDC recommends using NAATs to screen and diagnose for NG and CT in the
      genitourinary tract due to their superior sensitivity compared to traditional culture
      methods. The sensitivity and specificity of commercially available NAATs for the detection of
      urogenital NG and CT is estimated to be between 90-100%. The CDC also recommends using NAATs
      for screening and diagnosis of NG and CT in extragenital sites. Due to widespread use and
      interest in these tests for extragenital NG and CT infections, multiple studies have examined
      the test characteristics of NAAT tests in comparison to culture and to additional NAAT
      platforms. For diagnosis of CT, reported sensitivities are 80-100% (pharyngeal) and 46-100%
      (rectal), with significant variation by platform tested. Reported specificities are &gt;99% for
      pharyngeal site and 89-100% for the rectum. For diagnosis of NG, reported sensitivities are
      72-100% (pharyngeal) and 75-100% (rectal), again with variation by platform. Reported
      specificities are 72-100% (pharyngeal) and 95-100% (rectal).

      Despite the CDC's recommendations, however, there are currently no FDA-approved commercial
      NAAT tests for the detection of pharyngeal and rectal NG or CT infections. The FDA's
      clearance of such assays would increase the ability to diagnose and control NG and CT
      extragenital infections. This research study will help provide the data required for FDA
      consideration to clear such assays for marketing.

      Design &amp; Procedures: This will be a cross-sectional, single visit study evaluating the
      performance of three commercial NAATs to detect NG and CT in the rectum and pharynx. A fourth
      NAAT is being used as a tiebreaker. The performance of the fourth NAAT will not be evaluated.
      Each manufacturer will provide a specific collection kit and transport media.

      This research study will take place at healthcare clinics which focus on sexually transmitted
      diseases, women's health, student health, family planning clinics, and clinics specializing
      in lesbian, gay, bisexual, and transgender (LGBT) health. This research will include
      specimens collected from 2,500 adult males, females, and transgender persons who are seeking
      sexually transmitted disease (STD) testing at the participating study clinics. Both
      symptomatic and asymptomatic subjects will be included in the study population.

      Potential subjects will be identified, assessed for eligibility, and asked to provide oral
      informed consent. If they agree to take part in the research, study subjects will have eight
      swabs collected: four pharyngeal and four rectal. The swabs needed for routine clinical care
      will be taken first. All study procedures will take place during one clinic visit. There will
      not be a follow-up visit as part of this study. Subjects will continue with routine clinical
      care as directed by their medical providers.

      Subject participation will be confidential and anonymous. The results of the tests and
      subject participant in this research will not be placed in the subjects' medical records.

      Each study swab will be used for a specific NAAT, which will be run at one of the two
      reference testing laboratories. The Anatomic Site Infection Status (ASIS) will be defined by
      the results of the two other NAATs, and, if necessary, a tiebreaker test. Each anatomic site
      will be considered in isolation. If fewer than four swabs at a site are completed, that
      anatomic site (and swab results) will be excluded from the analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">March 12, 2018</completion_date>
  <primary_completion_date type="Actual">March 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All information collected anonymously.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Anatomic Site Infected Status (ASIS) for each anatomic site and each organism</measure>
    <time_frame>1 day</time_frame>
    <description>For each NAAT, the ASIS will be determined for each anatomic site (pharyngeal and rectal) and each organism (NG and CT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomic Site Infected Status (ASIS) by sex</measure>
    <time_frame>1 day</time_frame>
    <description>For each NAAT, the anatomic site infected status (ASIS) will be determined for each anatomic site (pharyngeal and rectal) and each organism (NG and CT) by sex .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomic Site Infected Status (ASIS) by symptom status</measure>
    <time_frame>1 day</time_frame>
    <description>For each NAAT, the anatomic site infected status (ASIS) will be determined for each anatomic site (pharyngeal and rectal) and each organism (NG and CT) by symptom status.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2767</enrollment>
  <condition>Neisseria Gonorrhoeae Infection</condition>
  <condition>Chlamydia Trachomatis Infection</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <arm_group>
    <arm_group_label>NAAT 1 to Detect Rectal NG and CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 1, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a rectal swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAAT 1 to Detect Pharyngeal NG and CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 1, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a pharyngeal swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAAT 2 to Detect Rectal NG and CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 2, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a rectal swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAAT 2 to Detect Pharyngeal NG and CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 2, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a pharyngeal swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAAT 3 to Detect Rectal NG and CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 3, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a rectal swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAAT 3 to Detect Pharyngeal NG and CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 3, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis from a pharyngeal swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAAT 4 to Detect Rectal and Pharyngeal NG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 4, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae from rectal and pharyngeal swabs. To be used as a tiebreaker if reference tests disagree.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAAT 4 to Detect Rectal and Pharyngeal CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of nucleic acid amplification test assay number 4, estimating the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Chlamydia trachomatis from rectal and pharyngeal swabs. To be used as a tiebreaker if reference tests disagree.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAAT 1 to Detect Rectal and Pharyngeal NG and CT</intervention_name>
    <description>Nucleic acid amplification assay test 1 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis in the rectum and pharynx.</description>
    <arm_group_label>NAAT 1 to Detect Rectal NG and CT</arm_group_label>
    <arm_group_label>NAAT 1 to Detect Pharyngeal NG and CT</arm_group_label>
    <other_name>Nucleic Acid Amplification Test 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAAT 2 to Detect Rectal and Pharyngeal NG and CT</intervention_name>
    <description>Nucleic acid amplification assay test 2 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis in the rectum and pharynx.</description>
    <arm_group_label>NAAT 2 to Detect Rectal NG and CT</arm_group_label>
    <arm_group_label>NAAT 2 to Detect Pharyngeal NG and CT</arm_group_label>
    <other_name>Nucleic Acid Amplification Test 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAAT 3 to Detect Rectal and Pharyngeal NG and CT</intervention_name>
    <description>Nucleic acid amplification assay test 3 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis in the pharynx and rectum.</description>
    <arm_group_label>NAAT 3 to Detect Rectal NG and CT</arm_group_label>
    <arm_group_label>NAAT 3 to Detect Pharyngeal NG and CT</arm_group_label>
    <other_name>Nucleic Acid Amplification Test 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAAT 4 to Detect Rectal and Pharyngeal NG</intervention_name>
    <description>Nucleic acid amplification assay test 4 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae in the rectum and pharynx. Test 4 will be used as a tiebreaker assay in case of disagreement between the reference NAAT results.</description>
    <arm_group_label>NAAT 4 to Detect Rectal and Pharyngeal NG</arm_group_label>
    <other_name>Nucleic Acid Amplification Test 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAAT 4 to Detect Rectal and Pharyngeal CT</intervention_name>
    <description>Nucleic acid amplification assay test 4 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Chlamydia trachomatis in the rectum and pharynx. Test 4 will be used as a tiebreaker assay in case of disagreement between the reference NAAT results.</description>
    <arm_group_label>NAAT 4 to Detect Rectal and Pharyngeal CT</arm_group_label>
    <other_name>Nucleic Acid Amplification Test 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Attending a participating clinic for evaluation of STIs

          2. ≥18 years of age at date of screening

          3. Able and willing to provide informed consent

          4. Willing to comply with study procedures, including collection of 4 swabs each from the
             pharynx and rectum for NG and CT testing

        Exclusion Criteria:

          1. Receipt of any systemic antibacterial drug in the past 14 days

          2. Receipt of myelosuppressive chemotherapy in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey D Klausner, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA David Geffen School of Medicine and Fielding School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIDS Health Foundation - Hollywood</name>
      <address>
        <city>Hollywood</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles LGBT Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liu B, Roberts CL, Clarke M, Jorm L, Hunt J, Ward J. Chlamydia and gonorrhoea infections and the risk of adverse obstetric outcomes: a retrospective cohort study. Sex Transm Infect. 2013 Dec;89(8):672-8. doi: 10.1136/sextrans-2013-051118. Epub 2013 Sep 4.</citation>
    <PMID>24005255</PMID>
  </reference>
  <reference>
    <citation>O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore). 1983 Nov;62(6):395-406.</citation>
    <PMID>6415361</PMID>
  </reference>
  <reference>
    <citation>Weström L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992 Jul-Aug;19(4):185-92.</citation>
    <PMID>1411832</PMID>
  </reference>
  <reference>
    <citation>Røttingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis. 2001 Oct;28(10):579-97. Review.</citation>
    <PMID>11689757</PMID>
  </reference>
  <reference>
    <citation>Deguchi T, Yasuda M, Ito S. Management of pharyngeal gonorrhea is crucial to prevent the emergence and spread of antibiotic-resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2012 Jul;56(7):4039-40; author re[ply 4041-2. doi: 10.1128/AAC.00505-12.</citation>
    <PMID>22700700</PMID>
  </reference>
  <reference>
    <citation>Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. Erratum in: MMWR Recomm Rep. 2015 Aug 28;64(33):924.</citation>
    <PMID>26042815</PMID>
  </reference>
  <reference>
    <citation>Zakher B, Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for gonorrhea and Chlamydia: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014 Dec 16;161(12):884-93. doi: 10.7326/M14-1022. Review.</citation>
    <PMID>25244000</PMID>
  </reference>
  <reference>
    <citation>Ota KV, Tamari IE, Smieja M, Jamieson F, Jones KE, Towns L, Juzkiw J, Richardson SE. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Transm Infect. 2009 Jun;85(3):182-6. doi: 10.1136/sti.2008.034140. Epub 2009 Jan 6.</citation>
    <PMID>19126571</PMID>
  </reference>
  <reference>
    <citation>Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis. 2008 Jul;35(7):637-42. doi: 10.1097/OLQ.0b013e31817bdd7e.</citation>
    <PMID>18520976</PMID>
  </reference>
  <reference>
    <citation>Trebach JD, Chaulk CP, Page KR, Tuddenham S, Ghanem KG. Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures. Sex Transm Dis. 2015 May;42(5):233-9. doi: 10.1097/OLQ.0000000000000248.</citation>
    <PMID>25868133</PMID>
  </reference>
  <reference>
    <citation>Bachmann LH, Johnson RE, Cheng H, Markowitz L, Papp JR, Palella FJ Jr, Hook EW 3rd. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol. 2010 May;48(5):1827-32. doi: 10.1128/JCM.02398-09. Epub 2010 Mar 24.</citation>
    <PMID>20335410</PMID>
  </reference>
  <reference>
    <citation>Cosentino LA, Campbell T, Jett A, Macio I, Zamborsky T, Cranston RD, Hillier SL. Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infections. J Clin Microbiol. 2012 Jun;50(6):2005-8. doi: 10.1128/JCM.00185-12. Epub 2012 Apr 4.</citation>
    <PMID>22493338</PMID>
  </reference>
  <reference>
    <citation>Geelen TH, Rossen JW, Beerens AM, Poort L, Morré SA, Ritmeester WS, van Kruchten HE, van de Pas MM, Savelkoul PH. Performance of cobas® 4800 and m2000 real-time™ assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and self-collected vaginal specimen. Diagn Microbiol Infect Dis. 2013 Oct;77(2):101-5. doi: 10.1016/j.diagmicrobio.2013.06.020. Epub 2013 Jul 23.</citation>
    <PMID>23891224</PMID>
  </reference>
  <reference>
    <citation>Moncada J, Schachter J, Liska S, Shayevich C, Klausner JD. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of nucleic acid amplification tests. J Clin Microbiol. 2009 Jun;47(6):1657-62. doi: 10.1128/JCM.02269-08. Epub 2009 Apr 15.</citation>
    <PMID>19369445</PMID>
  </reference>
  <reference>
    <citation>Perry MD, Jones RN, Corden SA. Is confirmatory testing of Roche cobas 4800 CT/NG test Neisseria gonorrhoeae positive samples required? Comparison of the Roche cobas 4800 CT/NG test with an opa/pap duplex assay for the detection of N gonorrhoeae. Sex Transm Infect. 2014 Jun;90(4):303-8. doi: 10.1136/sextrans-2013-051410. Epub 2014 Mar 20.</citation>
    <PMID>24653040</PMID>
  </reference>
  <reference>
    <citation>Harryman L, Scofield S, Macleod J, Carrington D, Williams OM, Fernandes A, Horner P. Comparative performance of culture using swabs transported in Amies medium and the Aptima Combo 2 nucleic acid amplification test in detection of Neisseria gonorrhoeae from genital and extra-genital sites: a retrospective study. Sex Transm Infect. 2012 Feb;88(1):27-31. doi: 10.1136/sextrans-2011-050075. Epub 2011 Oct 27.</citation>
    <PMID>22034496</PMID>
  </reference>
  <reference>
    <citation>Pope CF, Hay P, Alexander S, Capaldi K, Dave J, Sadiq ST, Ison CA, Planche T. Positive predictive value of the Becton Dickinson VIPER system and the ProbeTec GC Q x assay, in extracted mode, for detection of Neisseria gonorrhoeae. Sex Transm Infect. 2010 Nov;86(6):465-9. doi: 10.1136/sti.2010.044065.</citation>
    <PMID>20940160</PMID>
  </reference>
  <reference>
    <citation>Goldenberg SD, Finn J, Sedudzi E, White JA, Tong CY. Performance of the GeneXpert CT/NG assay compared to that of the Aptima AC2 assay for detection of rectal Chlamydia trachomatis and Neisseria gonorrhoeae by use of residual Aptima Samples. J Clin Microbiol. 2012 Dec;50(12):3867-9. doi: 10.1128/JCM.01930-12. Epub 2012 Sep 19.</citation>
    <PMID>22993183</PMID>
  </reference>
  <reference>
    <citation>Boyadzhyan B, Yashina T, Yatabe JH, Patnaik M, Hill CS. Comparison of the APTIMA CT and GC assays with the APTIMA combo 2 assay, the Abbott LCx assay, and direct fluorescent-antibody and culture assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol. 2004 Jul;42(7):3089-93.</citation>
    <PMID>15243065</PMID>
  </reference>
  <reference>
    <citation>Chernesky MA, Martin DH, Hook EW, Willis D, Jordan J, Wang S, Lane JR, Fuller D, Schachter J. Ability of new APTIMA CT and APTIMA GC assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol. 2005 Jan;43(1):127-31.</citation>
    <PMID>15634960</PMID>
  </reference>
  <reference>
    <citation>Moncada J, Donegan E, Schachter J. Evaluation of CDC-recommended approaches for confirmatory testing of positive Neisseria gonorrhoeae nucleic acid amplification test results. J Clin Microbiol. 2008 May;46(5):1614-9. doi: 10.1128/JCM.02301-07. Epub 2008 Mar 5.</citation>
    <PMID>18322062</PMID>
  </reference>
  <reference>
    <citation>Tabrizi SN, Unemo M, Limnios AE, Hogan TR, Hjelmevoll SO, Garland SM, Tapsall J. Evaluation of six commercial nucleic acid amplification tests for detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol. 2011 Oct;49(10):3610-5. doi: 10.1128/JCM.01217-11. Epub 2011 Aug 3.</citation>
    <PMID>21813721</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nucleic acid amplification tests</keyword>
  <keyword>Neisseria gonorrhoeae infection</keyword>
  <keyword>Chlamydia trachomatis infection</keyword>
  <keyword>Sexually transmitted diseases</keyword>
  <keyword>Pharynx</keyword>
  <keyword>Rectum</keyword>
  <keyword>Gram-Negative Bacterial Infections</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Genital Diseases, Male</keyword>
  <keyword>Genital Diseases, Female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
    <mesh_term>Gonorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

